Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Real-World-Wirksamkeit von Palbociclib + endokriner Therapie in der Erstlinie und nachfolgenden Behandlungen bei Patienten mit HR+/HER2- fortgeschrittenem Brustkrebs: Zwischenergebnisse der PERFORM-Studie.

G. Pfeiler, R. Bartsch, M. Korell, T. Gabrysiak, V. Petersen, M. Deryal, T. Fietz, J. Radosa, T. Decker, B. Schöttker, J. Knoblich, U. Rhein, N. Deuerling, M. Glasstetter, K. Gratzke, A. Buder, K. Lunglmeir, M. Czachorowski, J. Dzieran, M.P. Lux.

Poster präsentiert auf der 34. Jahrestagung der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Austria, 15. April 2026 – 18. April 2026, Salzburg, Österreich.

Poster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: AGO / Journal: -
PERFORM
2026
Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer in the real- world setting: Results from the PERFORM study.

R. Bartsch, M. Korell, G. Pfeiler, T. Gabrysiak, T. Fietz, M. Deryal, V. Petersen, T. Resch, B. Schöttker, T. Decker, L. Müller, J. Radosa, U. Rhein, M. Glasstetter, D. Klein, A. Buder, H. Kruger, A. Quartier, J. Dzieran, M.P. Lux.

J Clin Oncol 44, 1061-1061(2026).
DOI:10.1200/JCO.2026.44.16_suppl.1061

AbstractPoster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
PERFORM
2026
Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer in the real- world setting: Results from the PERFORM study.

R. Bartsch, M. Korell, G. Pfeiler, T. Gabrysiak, T. Fietz, M. Deryal, V. Petersen, T. Resch, B. Schöttker, T. Decker, L. Müller, J. Radosa, U. Rhein, M. Glasstetter, U. Oppermann, A. Buder, H. Kruger, A. Quartier, J. Dzieran, M.P. Lux.

Senologie 2026 ; 23 : e1 – e52.

Poster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal: Senologie
PERFORM
2026
Real-world effectiveness of 2nd-line treatments following 1L palbociclib + endocrine therapy: Preliminary results from the Non-Interventional Study PERFORM.

M.P. Lux, M. Korell, G. Pfeiler, T. Gabrysiak, T. Fietz, M. Deryal, V. Petersen, T. Resch, B. Schöttker, T. Decker, L. Müller, J. Radosa, U. Rhein, M. Glasstetter, K. Gratzke, B. Sauer, A. Quartier, J. Dzieran, M. Cubas Cordova, R. Bartsch.

ESMO Open Volume 11, Supplement 4107485, 2026.

AbstractPoster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: ESMO Open
PERFORM
2026
Routine treatment of elderly patients with advanced ovarian and endometrial cancer: data from the registry platform SMARAGD.

K. Gratzke, I. Juhasz-Boess, E. Stickeler, M. Korell, M. Zaiss, A. Nusch, O. Tomé, M. Jänicke, S. Winter, L. Kruggel, N. Wetzel, P. Buderath, S. Mann, B. Rabenbauer, A. Wöckel, A. Welt, D. Watermann, T. Decker.

International Journal of Gynecological Cancer, 36. DOI: 10.1016/j.ijgc.2025.103644

Poster

Indikation: Endometrial Cancer, Endometriumkarzinom, Ovarialkarzinom, Ovarian Cancer / Veranstaltung: ESGO / Journal: International Journal of Gynecological Cancer
SMARAGD
2026
Reliable segregation of survival under immunotherapy in NSCLC using simple clinical parameters.

P. Christopoulos, M. Sebastian, W. Eberhardt, A. Rittmeyer, M. Reck, J. Alt, K. Kokowski, P. Sadjadian, D. Heigener, K. Schneider, A. Fleitz, M. Jänicke, P. Ludwig, M. Groschek, M.-O. Zahn, T. Dechow, T. Fietz, H. Pelz, F. Griesinger, M. Thomas.

Oncol Res Treat 2026;49(suppl 1):10–335

Poster

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CRISP
2026
Prevalence of FGFR2b expression, characteristics, treatment and outcomes in patients with metastatic gastric and gastroesophageal junction adenocarcinoma in Germany.

L.J. Haug, K. Ringwald, A. Binninger, L. Tzala, K. Isse, R. Winkelmann, P. Stenzel, E. von der Heyde, C. Müller, D. Semsek, A. Servatius, I. Majer, H. Honeycutt, F. Lordick, P.J. Wild, M. Jaenicke, K.M. Potthoff

Annals of Oncology, 37S195. DOI:10.1016/j.annonc.2026.05.566

AbstractPoster

Indikation: Esophageal Cancer, Gastric Cancer, Magenkarzinom, Speiseröhrenkrebs / Veranstaltung: ESMO / Journal: Annals of Oncology
SAPHIR
2026
Treatment patterns, outcome and QoL of ES-SCLC patients receiving third-line therapy – Data from the German CRISP Registry (AIO-TRK-0315)

Rost, M; Fischer, R; Reck, M; Gauler, T; Waller, C; Christopoulos, P; Hoffknecht, P; Jänicke, M; Fleitz, A; Härzschel, A; Lennartz, C; Ludwig, P; Groth, A; Bendel, M; Stratmann, J; Griesinger, F; Thomas, M; Eberhardt, W; Sebastian, M.

Oncol Res Treat (2026) 49 (Suppl. 1): 1.

Abstract
Poster

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CRISP
2026
Real-World Incidence of Bleeding Events in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib +/- Obinutuzumab and Requiring Direct Oral Anticoagulation.

K Fenchel, E von der Heyde, M Zaiss, T Illmer, M Schulze, S Schroeder, D Kummer, Stefan Jäger, P Marschner.

Oncol Res Treat (2026) 49 (Suppl. 1): 1.

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CICERO
2026
Real-world evidence for oncology patients with rare NTRK gene fusions: Final results from the German multicenter patient cohort study REALTRK.

Karin Potthoff, Sebastian Lange, Thomas Seufferlein, Christoph Benedikt Westphalen, Rainer Claus, Annalen Bleckmann, Matthias Zaiss, Sina Grebhardt, Sophie Koszinowski, Larissa E Hillebrand, Kai Ringwald, Benjamin Kasenda for the REALTRK Registry Group.

JCO Precis Oncol 10, e2600283(2026).

Abstract

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: - / Journal: JCO Precision Oncology
REALTRK
2026